News & Insights

Stay Informed With Our Latest Updates

Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.

Insights > Keyword
Insights > Type
Global > Practices
Global > Industries
Insights > Location
Insights > Person
Insights > Date Filter
4201 Results Found

Firm News July 15, 2026

Gibson Dunn Advised ERock on Initial Public Offering

Gibson Dunn advised ERock, Inc. on its initial public offering. ERock is a leader in reliable, large-scale onsite power solutions.

Firm News May 4, 2026

Gibson Dunn Advises SLB on $2 Billion Offering of Senior Notes

Gibson Dunn is advising SLB on its $2 billion offering of Senior Notes.

Client Alert April 1, 2026

Digital Assets Recent Updates – February/March 2026

We are pleased to provide you with the February and March edition of Gibson Dunn’s digital assets regular update. This update covers recent legal news regarding all types of digital assets, including cryptocurrencies, stablecoins, CBDCs, and NFTs, as well as other blockchain and Web3 technologies. Thank you for your interest.

Firm News March 24, 2026

Gibson Dunn Advised Hewlett Packard Enterprise Company on $2 Billion Senior Notes Offering

Gibson Dunn advised Hewlett Packard Enterprise Company on its offering of $2 billion in senior notes.

Firm News February 17, 2026

Gibson Dunn Advised Galecto on Public Offering of Common Stock

Gibson Dunn advised Galecto, Inc. on its public offering of common stock, which generated aggregate gross proceeds to the company of approximately $316 million.

Client Alert January 26, 2026

Clarifications, Reversals and Expansions: Corp Fin Delivers Helpful Updates to Guidance

The Division of Corporation Finance of the Securities and Exchange Commission issued several new and updated Compliance and Disclosure Interpretations …

Firm News January 12, 2026

Gibson Dunn Represented Arrowhead Pharmaceuticals on Concurrent Public Offerings of Convertible Notes, Common Stock, and Pre-Funded Warrants and Related Capped Call Transactions

Gibson Dunn represented Arrowhead Pharmaceuticals, Inc. on concurrent public offerings of convertible notes, common stock, and pre-funded warrants to purchase common stock for aggregate gross proceeds of $930 million to Arrowhead and capped call transactions relating to the convertible notes.

Firm News December 17, 2025

Gibson Dunn Advised Celanese Corporation on Concurrent $1.4 Billion Senior Notes Offering and $1.2 Billion Tender Offers

Gibson Dunn advised Celanese Corporation on its concurrent $1.4 billion senior notes offering and $1.2 billion tender offers